Helius Med Technolog (HSDT) 2.2000 $HSDT
Helius Medical Technologies Announces Pilot Study for PoNS(TM)
Business Wire - Tue Sep 23, 3:09PM CDT
Helius Medical Technologies, Inc. (CSE:HSM) ("HMT", or the "Company"
announced today that its flagship PoNS(TM) technology would be tested in a double-blind, randomized, sham-controlled pilot efficacy study in volunteer human subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI). The PoNS(TM), an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (TBI). The study is being conducted at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. HMT is developing a commercial version of the prototype PoNS(TM) device used in the trial.
Helius Announces Pilot Studies for PoNS(tm) University of Wisconsin - Madison to Study Non-Invasive Neurostimulation Device for Brain-Injured Individuals
ACCESSWIRE - Tue Sep 23, 8:17AM CDT
NEWTOWN, PA AND VANCOUVER, BC / ACCESSWIRE / September 23, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("HMT", or the "Company" announced today that its flagship PoNS(TM) technology would be tested in a double-blind, randomized, sham-controlled pilot efficacy study in volunteer human subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI). The PoNS(TM), an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (TBI). The study is being conducted at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. HMT is developing a commercial version of the prototype PoNS(TM) device used in the trial.
Helius Medical Technologies, Inc. to Present at Euro Pacific Capital's 4th Annual Global Investment Conference
ACCESSWIRE - Thu Sep 04, 11:44AM CDT
NEWTOWN, PENNSYLVANIA AND VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / September 4, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("Helius" or the "Company" is pleased to announce its participation in the upcoming Global Investment Conference sponsored by Peter Schiff's Euro Pacific Capital on Tuesday, September 9th, 2014.
Helius Medical Technologies, Inc. Announces Consulting Agreement and Grant of Options
ACCESSWIRE - Mon Jul 14, 8:58PM CDT
NEWTOWN, PENNSYLVANIA AND VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / July 14, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("Helius" or the "Company" is pleased to announce that it has retained Brian Bapty, Ph.D., as a consultant. Dr. Bapty received his Ph.D. in Experimental Medicine and his B.Sc. in Cell and Developmental Biology from the University of British Columbia. His extensive experience in capital markets and prior work with institutional investors will be invaluable as the Company continues to attract investor interest and build shareholder value with the development of its patent pending technology that is believed will enable the first non-invasive means for delivering neurostimulation through the oral cavity (the "PoNSTM" .
Helius Medical Technologies Announces Pilot Study for PoNS(TM)
Business Wire - Tue Sep 23, 3:09PM CDT
Helius Medical Technologies, Inc. (CSE:HSM) ("HMT", or the "Company"
announced today that its flagship PoNS(TM) technology would be tested in a double-blind, randomized, sham-controlled pilot efficacy study in volunteer human subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI). The PoNS(TM), an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (TBI). The study is being conducted at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. HMT is developing a commercial version of the prototype PoNS(TM) device used in the trial. Helius Announces Pilot Studies for PoNS(tm) University of Wisconsin - Madison to Study Non-Invasive Neurostimulation Device for Brain-Injured Individuals
ACCESSWIRE - Tue Sep 23, 8:17AM CDT
NEWTOWN, PA AND VANCOUVER, BC / ACCESSWIRE / September 23, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("HMT", or the "Company"
announced today that its flagship PoNS(TM) technology would be tested in a double-blind, randomized, sham-controlled pilot efficacy study in volunteer human subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI). The PoNS(TM), an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (TBI). The study is being conducted at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. HMT is developing a commercial version of the prototype PoNS(TM) device used in the trial. Helius Medical Technologies, Inc. to Present at Euro Pacific Capital's 4th Annual Global Investment Conference
ACCESSWIRE - Thu Sep 04, 11:44AM CDT
NEWTOWN, PENNSYLVANIA AND VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / September 4, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("Helius" or the "Company"
is pleased to announce its participation in the upcoming Global Investment Conference sponsored by Peter Schiff's Euro Pacific Capital on Tuesday, September 9th, 2014. Helius Medical Technologies, Inc. Announces Consulting Agreement and Grant of Options
ACCESSWIRE - Mon Jul 14, 8:58PM CDT
NEWTOWN, PENNSYLVANIA AND VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / July 14, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("Helius" or the "Company"
is pleased to announce that it has retained Brian Bapty, Ph.D., as a consultant. Dr. Bapty received his Ph.D. in Experimental Medicine and his B.Sc. in Cell and Developmental Biology from the University of British Columbia. His extensive experience in capital markets and prior work with institutional investors will be invaluable as the Company continues to attract investor interest and build shareholder value with the development of its patent pending technology that is believed will enable the first non-invasive means for delivering neurostimulation through the oral cavity (the "PoNSTM" . 
